231 related articles for article (PubMed ID: 35927166)
1. Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer.
Sumodhee S; Guo L; Bouhlel L; Picard A; Otto J; Naghavi AO; Richier Q; Lévy A; Bondiau PY; Poudenx M; Passeron T; Lacour JP; Montaudié H; Doyen J
Cancer Radiother; 2022 Nov; 26(8):1045-1053. PubMed ID: 35927166
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer.
Wang P; Yin T; Zhao K; Yu J; Teng F
J Cancer Res Clin Oncol; 2022 May; 148(5):1253-1261. PubMed ID: 34812931
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review.
Rodríguez Plá M; Dualde Beltrán D; Ferrer Albiach E
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769050
[No Abstract] [Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
6. The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma.
Tracz JA; Donnelly BM; Ngu S; Vojnic M; Wernicke AG; D'Amico RS
J Neurooncol; 2023 May; 163(1):1-14. PubMed ID: 37086369
[TBL] [Abstract][Full Text] [Related]
7. Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups.
Trommer M; Adams A; Celik E; Fan J; Funken D; Herter JM; Linde P; Morgenthaler J; Wegen S; Mauch C; Franklin C; Galldiks N; Werner JM; Kocher M; Rueß D; Ruge M; Meißner AK; Baues C; Marnitz S
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267546
[TBL] [Abstract][Full Text] [Related]
8. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
10. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and tolerability.
Backlund E; Grozman V; Egyhazi Brage S; Lewensohn R; Lindberg K; Helgadottir H
Acta Oncol; 2023 Dec; 62(12):1921-1930. PubMed ID: 37966921
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
13. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
Front Immunol; 2021; 12():716317. PubMed ID: 34777340
[TBL] [Abstract][Full Text] [Related]
14. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
[TBL] [Abstract][Full Text] [Related]
15. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
Ruiz-Patiño A; Barrón F; Cardona AF; Corrales L; Mas L; Martín C; Zatarain-Barrón ZL; Recondo G; Ricaurte L; Rojas L; Archila P; Rodríguez J; Sotelo C; Viola L; Vargas C; Carranza H; Otero J; Pino LE; Rolfo C; Rosell R; Arrieta O;
Thorac Cancer; 2020 Sep; 11(9):2552-2560. PubMed ID: 32705787
[TBL] [Abstract][Full Text] [Related]
16. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
[TBL] [Abstract][Full Text] [Related]
17. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
[TBL] [Abstract][Full Text] [Related]
18. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
19. Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.
Samuel E; Lie G; Balasubramanian A; Hiong A; So Y; Voskoboynik M; Moore M; Shackleton M; Haydon A; John T; Mitchell PLR; Markman B; Briggs P; Parakh S
Clin Lung Cancer; 2021 May; 22(3):e425-e430. PubMed ID: 32778511
[TBL] [Abstract][Full Text] [Related]
20. Improved survival outcome with not-delayed radiotherapy and immediate PD-1/PD-L1 inhibitor for non-small-cell lung cancer patients with brain metastases.
Yu Y; Chen H; Tian Z; Zhang Q; Shui Y; Shen L; Hu Q; Huang Z; Zhu S; Jiang H; Wei Q
J Neurooncol; 2023 Oct; 165(1):127-137. PubMed ID: 37848757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
